


Contents lists available at ScienceDirect

Protein Expression and Purification



journal homepage: www.elsevier.com/locate/yprep

Optimized production of insulin variant, a recombinant platelet aggregation inhibitor, by high cell-density fermentation of recombinant *Escherichia coli*



Jian Jing*, Yaoling Chen, Li Sheng, Mi Wu

Beijing Key Lab of Genetic Engineering and Biotechnology, College of Life Sciences, Beijing Normal University, Beijing, 100875, China

A R TICLEINFO A B S T R A C T Keywords: Optimal conditions for a high cell-density fermentation of Escherichia coli strain harboring a recombinant anti-thrombosis insulin variant High cell-density fermentation Fed-batch Platelet aggregation inhibition NaCl 5 g/L. The late-stage induction with 0.05 mM isopropyl-β-D- thiogalactopyranoside showed the highest productivity after 28 h of the fed-batch fermentation. This optimized process yielded about 150 mg of purified rAT-INS from 1 L of wet cell mass with high-homogeneity. The amino acid compositions and mass data of the purified rAT-INS were in good agreement with those as expected. Purified rAT-INS exhibited potent inhibitory activity of platelet aggregation. The in vivo assay showed that rAT-INS had a higher activity in prolonging the

1. Introduction

Heterologous expression of naturally scarce eukaryotic proteins in *Escherichia coli* has provided abundant source of these proteins for clinical use. Levels of foreign gene expression in *E. coli* are highly system-specific depending on biochemical characteristics of the recombinant proteins, induction mechanism of gene expression, host strains, and cultivation conditions. High cell-density fermentation is a useful process for improving the production yield of recombinant proteins. Understanding the relationship between microbial physiology, host-vector system, and gene expression during fermentation is essential to optimize the production of recombinant proteins [1].

Up to now, fed-batch culture technique has been mainly used for high cell-density fermentation of recombinant *E. coli*. To supply nutrients to the fermentor in fed-batch culture, various feeding systems have been developed, such as predetermined feeding system, DO-stat system, pH-stat system and system using on-line glucose analysis. Under excessive glucose concentration even in the aerobic condition, *E. coli* produces acetate, which inhibits cell growth and product synthesis known as *E. coli* Crabtree effect [2–4]. Among the various factors to be considered for high productivity in a fermentation process, acetate concentration is one important factor. Therefore, for high density culture of recombinant *E. coli* by fed-batch culture technique, it is desirable to maintain DO concentration above 10% of that saturated by air, and glucose concentration at low level to inhibit acetate accumulation [5]. The optimum concentration of nitrogen source in relation to the carbon source is also important to achieve high cell-density and high productivity of targeted recombinant proteins.

bleeding time in mice than native-insulin. The purified rAT-INS had almost no insulin receptor binding activity.

Our study demonstrates the promise for mass production of novel recombinant antiplatelet agents.

Platelet aggregation is a crucial step in thrombotic events and involves the binding of fibrinogen to activated platelets. Since RGD motif mediates the interaction of fibrinogen with cell surface receptors, RGD-containing proteins or peptides have the potency to inhibit platelet aggregation and could be used in the treatment of thrombotic diseases [6]. In our previous study, we introduced RGD motif into an inactive human proinsulin to construct a recombinant anti-thrombosis insulin variant (named rAT-INS). rAT-INS exhibited inhibitory activity of platelet aggregation with an IC50 value of 0.35 μ M [6]. However, large scale expression and purification of rAT-INS is challenging in order to maximize the yield and maintain the biological activity of rAT-INS.

In this study, we investigated and optimized the medium composition and induction process of rAT-INS expression for high cell-density culture of recombinant *E. coli*. In addition, we developed an efficient protocol for the high recovery of rAT-INS expressed in *E. coli* as cytoplasmic inclusion bodies.

2. Materials and methods

2.1. Materials

The E. coli host strain used in this study was E. coli BL21(DE3) PLysS

https://doi.org/10.1016/j.pep.2018.07.001

Received 20 May 2018; Received in revised form 27 June 2018; Accepted 2 July 2018 Available online 03 July 2018 1046-5928/ © 2018 Elsevier Inc. All rights reserved.

^{*} Corresponding author.

E-mail address: jjing@bnu.edu.cn (J. Jing).

[F⁻, ompT, RB⁻, MB⁻] whose chromosome carries the gene for *T*7 RNA polymerase, *lac*I gene and *lacUV5* promoter gene. The pET-3a-PICh plasmid harboring rAT-INS gene was constructed by us and described previously [6]. The *E. coli* strain containing the plasmid was designed as BL/pET-PICh. When expressed in recombinant *E. coli* strain, rAT-INS was accumulated as inclusion bodies. Isopropyl-β-D- thiogalactopyranoside (IPTG) was obtained from Sigma, USA. All other chemicals used were of analytical grade obtained from local companies. Trace element stock solution contained following compounds: FeCl₃·6H₂O 3.24 g/L, ZnCl₂ 0.22 g/L, CoCl₂·6H₂O 0.24 g/L, Na-MoO₄·2H₂O 0.24 g/L, CaCl₂·2H₂O 0.12 g/L, CuSO₄·5H₂O 0.20 g/L, H₃BO₃ 1.0 g/L, and MgSO₄ 0.74 g/L.

2.2. High cell-density fermentation of recombinant E. coli

Controlled fermentations were performed in a BIO-FLU-10 L fermentor (New Brunswick Scientific Co.), equipped with an embedded multi-loop controller which regulated agitation, temperature, dissolved oxygen, pH and nutrient. The recombinant E. coli BL/pET-PICh was cultured in 100 mL of the seed medium: 3% yeast extract, 1% tryptone, and 0.5% NaCl (w/v) supplemented with $100 \,\mu\text{g/mL}$ of ampicillin at 37 °C. This seed culture was transferred with 1% (v/v) inoculums to a 10 L jar fermentor containing 5 L of growth medium (glycerol 10 g/L, yeast extract 30 g/L, tryptone 10 g/L, NaCl 5 g/L, KH₂PO₄ 2.0 g/L, K₂HPO₄ 0.5 g/L, MgSO₄·7H₂O 1.0 g/L, FeSO₄·7H₂O 0.20 g/L, CaCl₂·2H₂O 0.01 g/L, pH 7.0) and then fermented at 37 °C. Nutrient addition by pH-stat method was controlled with advanced fermentation Software. During fermentation, air and/or pure oxygen were supplied at a rate of 1–1.5 vvm to maintain the dissolved oxygen concentration at 30–60%. The pH was controlled at 7.0 by 30% (v/v) phosphoric acid as the acid and 25% (v/v) ammonium hydroxide as the base. Antifoam-A (Sigma, USA) was used to suppress foam formation. The optical density (OD) of each sample was measured at 600 nm with a UV-visible spectrophotometer (UltraspecIII, Pharmacia). One OD unit was experimentally determined to be 0.45 g dry cell weight/L. After 6 h of growth phase fermentation, the fed-batch process was initiated by adding 800-1200 mL of the feeding medium (glycerol 50 g/L, yeast extract 150 g/L, tryptone 50 g/L, MgSO₄ 0.5 g/L, and (NH₄)₂SO₄ 1.0 g/ L) at the constant rate of 30 m\$props_value{literPattern}/L/h. Expression level of the targeted recombinant proteins was examined with sodiumdodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and quantified by densitometry. IPTG was fed for the expression of recombinant rAT-INS at the late stage of fermentation. Plasmid stability was determined by counting colonies on agar-plates (LB medium) with and without 100 mg/L ampicillin.

2.3. Refolding and purification of rAT-INS

The fermented broth was centrifuged at 8000 rpm for 30 min at 4 °C, the pellet was washed twice with 50 mM phosphate buffer (pH 7.4) and lysed in lysis buffer (0.05 M Tris-HC1, 5% Triton, 8% sucrose, 0.05 M EDTA, pH 8.0) by sonication using a vibra cell sonicator (Sonics, USA) with a 19 mm-threaded probe at 40 kHz amplitude of power. The efficiency of cell lysis was optimized by employing different sonication time course. After sonication, the lysate was centrifuged at 4 °C for 30 min to recover the inclusion bodies which was then resuspended in wash buffer (50 mM Tris-HCl, 2.5 g/L TritonX-100, 2 mM EDTA, pH 8.0) and recovered by centrifugation at 25-28 °C for 30 min at 8000 rpm. The lysed pellet was collected by centrifugation at 10,000 g and suspended by stirring overnight at 10 °C with 4 vol of lysis buffer (8 M urea or 6 M guanidine-HC1, 1 mM DTT in 0.1 M Tris/HCl, pH 8.0). After centrifugation, DTT was added to the supernatant to a final concentration of 10 mM and the mixture was incubated at 37 °C for 1 h, then diluted with 4 vol of cold water, with pH adjusted to 4.0-5.0 for precipitation at 4 °C for 2 h. The pellet was collected by centrifugation, and quickly dissolved in 50 mL of cold water with pH adjusted to 10–12. Then the solution was diluted with 2 L of 0.05 M Glycine/NaOH buffer, pH 10.8, and kept at 4 °C overnight for refolding. After ultrafiltration, the refolded protein was loaded onto a Sephacryl S200 column (2 × 100 cm) using Watson Marlow peristaltic pump, and eluted with the formation buffer. The fraction containing rAT-INS was pooled, ultrafiltrated, and lyophilized.

2.4. Platelet aggregation inhibition assay

Blood was collected from a healthy human donor in 3.8% (w/v) sodium citrate (1:9 ratio) and was centrifuged at $150 \times g$ at room temperature for 10 min to obtain platelet-rich plasma. Samples with various concentrations of rAT-INS were incubated with 277 µl of platelet-rich plasma at 37 °C for 2 min before the addition of 3 µl of 300 µM adenosine 5'-diphosphate (ADP). The inhibition of platelet aggregation was determined by light transmission. IC₅₀ (molar concentration of peptide required to cause 50% inhibition of platelet aggregation) was calculated for each experiment.

2.5. Assay for bleeding time in mice

BALB/c mice (male, 20 g body weight) were obtained from Institute of Experimental Animal, Chinese Academy of Medicine Science. Bleeding time in mice was measured by the method described by Dejana et al. [7]. Solution of normal saline or various concentrations of rAT-INS was injected intravenously through a tail vein of the mouse. A cut of 4 mm from the tail of mouse was done 8 min after the injection. Bleeding time was recorded from the beginning of bleeding to its end.

2.6. Assay for insulin binding of rAT-INS

Insulin receptor was partially isolated as crude membranes from human placenta [8]. rAT-INS was then diluted into a series of concentrations in KRB buffer (0.119 mol L⁻¹ NaCl, 1.2 mmol L⁻¹ MgSO₄, 0.03 mol L⁻¹ HEPES, 0.05 mol L⁻¹ KCl, 1.2 mmol L⁻¹ KH₂PO₄, 1.3 mmol L⁻¹ CaCl₂, 0.01 mol L⁻¹ NaHCO₃, pH 7.4). Equal volume of diluted ¹²⁵I-insulin and six-fold diluted insulin receptor in KRB buffer containing 2% (w/v) of bovine serum albumin were added and mixed with rAT-INS. The mixtures were incubated overnight at 4 °C and then centrifuged at 10,000 g for 5 min. The radioactivity of the pellet was determined by γ -ray detection assay. Native human insulin with full receptor-binding activity and 0.9% NaCl was set as positive control and negative control, respectively.

2.7. Physicochemical properties of rAT-INS

Matrix-assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry of rAT-INS was performed at the Chemistry Research Institute Mass Spectrometry Research Centre, Academy of Nature Sciences of China. Purified and concentrated samples were applied to a Voyager-DE STR MALDI-TOF biospectrometry work station (Applied Biosystems) using sinapic acid as the matrix. Whole protein spectra were recorded in a linear mode and bovine serum albumin was used as the calibration marker. The thiol group was determined by Ellman's method [9]. SDS-PAGE and IEF were performed according to the Pharmacia method [10].

3. Results and discussion

3.1. Structural features of rAT-INS

Structural representation of AT-INS was shown in Fig. 1. The space distance between B30 site of B chain and A1 site of A chain is about 5–10 Å. With the similarity of structural characteristics between the C-peptide and the functional RGD motif, it is possible to display an RGD motif on the surface of mutant insulin. The structural simulation of rAT-

Download English Version:

https://daneshyari.com/en/article/8359225

Download Persian Version:

https://daneshyari.com/article/8359225

Daneshyari.com